发布求助
文献互助 智能选刊 最新文献

Mental Health Clinician最新文献

筛选
英文 中文
Antidepressant medications: The FDA-approval process and the need for updates 抗抑郁药物:fda批准程序和更新的需要
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186950
Conor Hanrahan, James P. New
{"title":"Antidepressant medications: The FDA-approval process and the need for updates","authors":"Conor Hanrahan, James P. New","doi":"10.9740/MHC.N186950","DOIUrl":"https://doi.org/10.9740/MHC.N186950","url":null,"abstract":"Antidepressant drug development first began in the mid-twentieth century with the discovery of monoamine oxidase inhibitors and tricyclic antidepressants. Soon after, additional molecular targets and drug entities were created, eventually leading to the development of selective serotonin reuptake inhibitors. Today, antidepressants now rank among the top 10 most commonly used medications in the United States (US) and account for over $11 billion in annual sales. To help ensure the safety and efficacy of these commonly used products, in 1977 the US Food and Drug Administration (FDA) created guidelines to standardize antidepressant studies and the approval process. Although many of the recommendations outlined by FDA are still relevant, the document remains vague when describing key aspects of antidepressant trial design and much of the clinical information is outdated by today's standards. This paper will provide a general overview of the FDA-approval process, summarize FDA's position related to antidepress...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"16 1","pages":"11-16"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87021970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Pharmacogenomic testing for treatment resistant depression 治疗难治性抑郁症的药物基因组学检测
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N207183
S. Leckband
{"title":"Pharmacogenomic testing for treatment resistant depression","authors":"S. Leckband","doi":"10.9740/MHC.N207183","DOIUrl":"https://doi.org/10.9740/MHC.N207183","url":null,"abstract":"The percentage of patients who have failed to completely or partially respond to multiple trials of antidepressants at adequate doses and for an adequate duration of therapy has varied in the literature and is considered substantial. Numerous strategies exist to treat poor antidepressant response, but often medications are selected on a “trial and error” basis. Genetic factors may play a role in poor response or intolerance to treatment with antidepressants which lead to treatment failures. Currently, available genetic testing as well as genetic testing currently under research may help guide clinicians with proper medication and dose selection.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"99 1","pages":"236-239"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75476052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilization of vitamins, herbals, and over-the-counter products to delay progression of dementia 使用维生素、草药和非处方产品来延缓痴呆症的进展
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N204527
Jami L. Butz
{"title":"Utilization of vitamins, herbals, and over-the-counter products to delay progression of dementia","authors":"Jami L. Butz","doi":"10.9740/MHC.N204527","DOIUrl":"https://doi.org/10.9740/MHC.N204527","url":null,"abstract":"Many consumers use alternative preparations such as herbals, vitamins, and over-the-counter products in an attempt to prevent or improve the outcome of dementia. Despite use by almost half of all patients, evidence supporting their utilization is either conflicting or lacking. Omega-3 fatty acids, vitamin B6, vitamin B12, vitamin C, and beta-carotene currently do not have clinical trials showing evidence impacting the progression or treatment of symptoms associated with dementia. In addition, conflicting data exist pertaining to the beneficial utilization of ginkgo biloba and nonsteroidal anti-inflammatory drugs associated with dementia treatment. While a link to the utility of folate associated with areas of improved cognitive functioning has been suggested, further studies are needed. Vitamin E may have some benefit in patients with Alzheimer's disease, however, may also have risks in patients with comorbid diseases such as cardiovascular disease or diabetes mellitus. With limited options still existing...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"69 1","pages":"196-200"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88873161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent changes in the treatment of hypertension 高血压治疗的最新变化
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N197964
Bridget Bradley, L. Carlson
{"title":"Recent changes in the treatment of hypertension","authors":"Bridget Bradley, L. Carlson","doi":"10.9740/MHC.N197964","DOIUrl":"https://doi.org/10.9740/MHC.N197964","url":null,"abstract":"Hypertension affects a large portion of the United States' population and is a significant risk factor for cardiovascular events. A variety of treatment guidelines exist including the American Diabetes Association, European Society of Hypertension/European Society of Cardiology and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. The following is a summary of these guidelines regarding the effective treatment of hypertension.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"64 1","pages":"143-145"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78632617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A review of the evidence supporting the use of lithium augmentation therapy for the reduction of suicidal behavior in patients with unipolar depression: Revisiting an overlooked benefit of an older medication 对支持使用锂增强疗法减少单极抑郁症患者自杀行为的证据的回顾:重新审视一种被忽视的旧药物的益处
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N207175
Elizabeth Jackson, Rene A. Endow-Eyer
{"title":"A review of the evidence supporting the use of lithium augmentation therapy for the reduction of suicidal behavior in patients with unipolar depression: Revisiting an overlooked benefit of an older medication","authors":"Elizabeth Jackson, Rene A. Endow-Eyer","doi":"10.9740/MHC.N207175","DOIUrl":"https://doi.org/10.9740/MHC.N207175","url":null,"abstract":"Major depressive disorder is a serious, recurrent condition with significant impact on a person's quality of life and functioning, which carries a significant risk of premature death due to suicide. There is evidence that supports the effectiveness of lithium as an augmentation strategy for treatment-resistant depression, as well as for reducing suicidality in this population. This review introduces several theories regarding the proposed mechanism behind lithium's anti-suicidal effects and summarizes a selection of the pertinent literature supporting lithium's beneficial effects on suicidality.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"29 1","pages":"221-225"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81020884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Antidepressant management of insomnia disorder in the absence of a mood disorder 无情绪障碍的失眠的抗抑郁药管理
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N188364
P. Nazarian, Susie H Park
{"title":"Antidepressant management of insomnia disorder in the absence of a mood disorder","authors":"P. Nazarian, Susie H Park","doi":"10.9740/MHC.N188364","DOIUrl":"https://doi.org/10.9740/MHC.N188364","url":null,"abstract":"Insomnia is the most common sleep disorder, and antidepressants are increasingly being used for its management. This article reviews the existing data concerning the use of antidepressants in the treatment of primary insomnia.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"37 1","pages":"41-46"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81381458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The long-term use of sedative hypnotics in chronic insomnia 长期使用镇静催眠药治疗慢性失眠症
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N190097
Chelsie B. Heesch
{"title":"The long-term use of sedative hypnotics in chronic insomnia","authors":"Chelsie B. Heesch","doi":"10.9740/MHC.N190097","DOIUrl":"https://doi.org/10.9740/MHC.N190097","url":null,"abstract":"Symptoms of insomnia are highly prevalent among adults and insomnia is often a chronic condition which may occur for years. Sedative hypnotics including benzodiazepines (BZDs), zolpidem, eszopiclone, and zaleplon (NBZDs) are commonly used to treat insomnia. The longest controlled studies evaluating the safety and efficacy of NBZDs were 12 months in duration and 2 months in duration for the BZD, temazepam. These studies suggest that NBZDs continue to be effective and safe when used for up to 12 months. The short-term adverse effects are more common and more severe for BZDs than for NBZDs. Despite the current practice of using sedative hypnotics for longer durations, studies have yet to evaluate the long-term adverse effect profile.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"11 1","pages":"78-81"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84174747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Screening, diagnosis, and management of type II diabetes: A review of the 2014 American Diabetes Association guidelines 2型糖尿病的筛查、诊断和管理:2014年美国糖尿病协会指南综述
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N194573
Sweta M Patel, A. Thompson
{"title":"Screening, diagnosis, and management of type II diabetes: A review of the 2014 American Diabetes Association guidelines","authors":"Sweta M Patel, A. Thompson","doi":"10.9740/MHC.N194573","DOIUrl":"https://doi.org/10.9740/MHC.N194573","url":null,"abstract":"Individuals with schizophrenia and schizoaffective disorders are at higher risk than the general population for the development of chronic medical conditions, such as type II diabetes. This review article will focus on the 2014 recommendations from the American Diabetes Association for diagnosis, management, and assessment of glycemic control in patients with type II diabetes","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"37 1","pages":"107-113"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82558761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Therapeutic drug monitoring with valproate-Why product selection is an important factor 丙戊酸治疗药物监测-为什么产品选择是重要因素
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186966
Dan McGraw
{"title":"Therapeutic drug monitoring with valproate-Why product selection is an important factor","authors":"Dan McGraw","doi":"10.9740/MHC.N186966","DOIUrl":"https://doi.org/10.9740/MHC.N186966","url":null,"abstract":"There is a modest collection of literature describing the pharmacokinetic and clinical differences between the extended-release form of divalproex sodium (Depakote ER ® ) and the delayed-release form (Depakote ® ). Published articles are quick to espouse the extended-release formulation, especially in the setting of seizure control. Reasons commonly cited include a longer dosing interval, improved patient compliance, a more consistent pharmacokinetic profile, and fewer side effects. There are fewer articles discussing these differences in the context of treating mental illnesses, namely bipolar affective disorder. This article aims to compare these two formulations of divalproex with a special focus on their pharmacokinetic profiles, uses in psychiatric illness, and the role of therapeutic drug monitoring. The patient case that follows will describe a scenario in which a patient was prescribed each formulation during an acute hospitalization.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"19 1","pages":"31-34"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75026947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
What is the difference? Within class comparisons of psychotropic agents with new products 有什么区别呢?精神药物与新产品的类内比较
Mental Health Clinician Pub Date : 2014-12-23 DOI: 10.9740/MHC.N186968
A. Vandenberg
{"title":"What is the difference? Within class comparisons of psychotropic agents with new products","authors":"A. Vandenberg","doi":"10.9740/MHC.N186968","DOIUrl":"https://doi.org/10.9740/MHC.N186968","url":null,"abstract":"When ‘new’ psychotropic medications are released on the market, it can be difficult to discern the differences between the newer agents and their similar predecessors. Since head to head clinical trials are rarely available, it is important to learn what can be gleaned from the package inserts and the Food and Drug Administration (FDA) website. These sources are a wealth of information and were used as the primary resources for the comparative tables that follow.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"19 1","pages":"2-7"},"PeriodicalIF":0.0,"publicationDate":"2014-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76905895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信